{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:47:29Z","timestamp":1789426049789,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12872-017-0686-z","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T07:25:53Z","timestamp":1507188353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"17","author":[{"given":"Chenhui","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihe","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-7368","authenticated-orcid":false,"given":"Dachun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"issue":"8","key":"686_CR1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, B\u00f6hm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail. 2012;14(8):803\u201369.","journal-title":"Eur J Heart Fail"},{"issue":"8875","key":"686_CR2","first-page":"821","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Group","year":"1993","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342(8875):821\u20138.","journal-title":"Lancet"},{"key":"686_CR3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"686_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"M Pfeffer","year":"1992","unstructured":"Pfeffer M, Braunwald E, Moy\u00e9 L, Basta L, Brown E, Cuddy T, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327(10):669\u201377.","journal-title":"N Engl J Med"},{"key":"686_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Investigators","year":"1991","unstructured":"Investigators S. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"issue":"25","key":"686_CR6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","volume":"333","author":"L K\u00f8ber","year":"1995","unstructured":"K\u00f8ber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting\u2013enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333(25):1670\u20136.","journal-title":"N Engl J Med"},{"issue":"8","key":"686_CR7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920\u20136.","journal-title":"Circulation"},{"issue":"5","key":"686_CR8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine\u2013isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303\u201310.","journal-title":"N Engl J Med"},{"issue":"9335","key":"686_CR9","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360(9335):752\u201360.","journal-title":"Lancet"},{"issue":"9215","key":"686_CR10","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582\u20137.","journal-title":"Lancet"},{"issue":"20","key":"686_CR11","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, K\u00f8ber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893\u2013906.","journal-title":"N Engl J Med"},{"issue":"10","key":"686_CR12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study: the RESOLVD pilot study investigators. Circulation. 1999;100(10):1056\u201364.","journal-title":"Circulation"},{"issue":"9386","key":"686_CR13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386):772\u20136.","journal-title":"Lancet"},{"issue":"9054","key":"686_CR14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","volume":"349","author":"B Pitt","year":"1997","unstructured":"Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747\u201352.","journal-title":"Lancet"},{"issue":"16","key":"686_CR15","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","volume":"33","author":"LC Vark van","year":"2012","unstructured":"van Vark LC, Bertrand M, Akkerhuis KM, Meurers G, Cowley AJ, Thomas I, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin\u2013angiotensin\u2013aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33(16):2088\u201397.","journal-title":"Eur Heart J"},{"issue":"5","key":"686_CR16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","volume":"174","author":"J Cheng","year":"2014","unstructured":"Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Inter Med. 2014;174(5):773\u201385.","journal-title":"JAMA Inter Med"},{"issue":"4","key":"686_CR17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"issue":"1","key":"686_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"issue":"1","key":"686_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","volume":"24","author":"AE Ades","year":"2006","unstructured":"Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. PharmacoEconomics. 2006;24(1):1\u201319.","journal-title":"PharmacoEconomics"},{"key":"686_CR20","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","volume":"15","author":"JP Higgins","year":"1996","unstructured":"Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med. 1996;15:2733\u201349.","journal-title":"Stat Med"},{"key":"686_CR21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897\u2013900.","journal-title":"BMJ"},{"key":"686_CR22","unstructured":"Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from \nhttp:\/\/training.cochrane.org\/handbook\n\n."},{"issue":"6","key":"686_CR23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/hrt.79.6.593","volume":"79","author":"CJ Bulpitt","year":"1998","unstructured":"Bulpitt CJ, Fletcher AE, D\u00f6ssegger L, Neiss A, Nielsen T, Viergutz S. Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Heart. 1998;79(6):593\u20138.","journal-title":"Heart"},{"issue":"1\u20132","key":"686_CR24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00192366","volume":"49","author":"J Widimsk\u00fd","year":"1995","unstructured":"Widimsk\u00fd J, Uhl\u00ed\u0159 O, Kremer HJ, Jerie P. Czech and Slovak spirapril intervention study (CASSIS). Eur J Clin Pharmacol. 1995;49(1\u20132):95\u2013102.","journal-title":"Eur J Clin Pharmacol"},{"key":"686_CR25","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/00005344-198700003-00021","volume":"9","author":"JP Chalmers","year":"1987","unstructured":"Chalmers JP, West MJ, Cyran J, De La Torre D, Englert M, Kramar M, et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol. 1987;9:S89\u201397.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"686_CR26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0002-9149(92)90618-9","volume":"70","author":"HT Colfer","year":"1992","unstructured":"Colfer HT, Ribner HS, Gradman A, Hughes CV, Kapoor A, Laidlaw JC. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am J Cardiol. 1992;70(3):354\u20138.","journal-title":"Am J Cardiol"},{"issue":"12","key":"686_CR27","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1093\/oxfordjournals.eurheartj.a060844","volume":"16","author":"L Erhardt","year":"1995","unstructured":"Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J. 1995;16(12):1892\u20139.","journal-title":"Eur Heart J"},{"issue":"8","key":"686_CR28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0002-9149(99)80624-9","volume":"75","author":"EJ Brown Jr","year":"1995","unstructured":"Brown EJ Jr, Chew PH, MacLean A, Gelperin K, Ilgenfritz JP. BlumenthalM. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol. 1995;75(8):596\u2013600.","journal-title":"Am J Cardiol"},{"issue":"3","key":"686_CR29","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/0002-8703(93)90933-Z","volume":"126","author":"P Lechat","year":"1993","unstructured":"Lechat P, Garnham SP, Desche P, Bounhoure JP. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J. 1993;126(3):798\u2013806.","journal-title":"Am Heart J"},{"issue":"3","key":"686_CR30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0002-9343(88)90221-5","volume":"84","author":"TJ Newman","year":"1988","unstructured":"Newman TJ, Maskin CS, Dennick LG, Meyer JH, Hallows BG, Cooper WH. Effects of captopril on survival in patients with heart failure. Am J Med. 1988;84(3):140\u20134.","journal-title":"Am J Med"},{"issue":"5","key":"686_CR31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00005344-199905000-00009","volume":"33","author":"J Cosin-Aguilar","year":"1999","unstructured":"Cosin-Aguilar J, Marrugat J, Sanz G, Mass\u00f3 J, Gil M, Vargas R, et al. Long-term results of the Spanish trial on treatment and survival of patients with predominantly mild heart failure. J Cardiovasc Pharmacol. 1999;33(5):733\u201340.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"686_CR32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejheart.2003.12.019","volume":"6","author":"M Komajda","year":"2004","unstructured":"Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, et al. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail. 2004;6(4):467\u201375.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"686_CR33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/eurjhf\/hfr051","volume":"13","author":"C Funck-Brentano","year":"2011","unstructured":"Funck-Brentano C, Veldhuisen DJ, Ven LLM, Follath F, Goulder M, Willenheimer R. Influence of order and type of drug (bisoprolol vs enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail. 2011;13(7):765\u201372.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"686_CR34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/BF00877401","volume":"8","author":"AJ Cowley","year":"1994","unstructured":"Cowley AJ, McEntegart DJ, Hampton JR, Barnett DB, Bexton RS, Boyle R, et al. Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril. Cardiovasc Drug Ther. 1994;8(6):829\u201336.","journal-title":"Cardiovasc Drug Ther"},{"issue":"3","key":"686_CR35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/hrt.78.3.285","volume":"78","author":"HJ Dohmen","year":"1997","unstructured":"Dohmen HJ, Dunselman PH, Poole-Wilson PA. Comparison of captopril and ibopamine in mild to moderate heart failure. Heart. 1997;78(3):285\u201390.","journal-title":"Heart"},{"issue":"4","key":"686_CR36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/0735-1097(92)90529-V","volume":"19","author":"GC Fonarow","year":"1992","unstructured":"Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19(4):842\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"9230","key":"686_CR37","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","volume":"356","author":"JL Rouleau","year":"2000","unstructured":"Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356(9230):615\u201320.","journal-title":"Lancet"},{"issue":"1","key":"686_CR38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1388-9842(98)00003-8","volume":"1","author":"DB Northridge","year":"1999","unstructured":"Northridge DB, Currie PF, Newby DE, McMurray JJ, Ford M, Boon NA, Dargie HJ. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail. 1999;1(1):67\u201372.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"686_CR39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0735-1097(95)80020-H","volume":"26","author":"K Dickstein","year":"1995","unstructured":"Dickstein K, Chang P, Willenheimer R, Hauns\u00f8 S, Remes J, Hall C, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26(2):438\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"686_CR40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0167-5273(02)00154-7","volume":"85","author":"R Willenheimer","year":"2002","unstructured":"Willenheimer R, Helmers C, Pantev E, Rydberg E, L\u00f6fdahl P, Gordon A. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol. 2002;85(2):261\u201370.","journal-title":"Int J Cardiol"},{"issue":"4","key":"686_CR41","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0735-1097(97)00253-2","volume":"30","author":"RM Lang","year":"1997","unstructured":"Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol. 1997;30(4):983\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"686_CR42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0167-5273(00)00426-5","volume":"77","author":"P Dunselman","year":"2001","unstructured":"Dunselman P. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure: the replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol. 2001;77(2):131\u20138.","journal-title":"Int J Cardiol"},{"issue":"5","key":"686_CR43","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0735-1097(98)00695-0","volume":"33","author":"EP Havranek","year":"1999","unstructured":"Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol. 1999;33(5):1174\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"686_CR44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0002-8703(00)90037-1","volume":"139","author":"CB Granger","year":"2000","unstructured":"Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139(4):609\u201317.","journal-title":"Am Heart J"},{"issue":"22","key":"686_CR45","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1161\/01.CIR.100.22.2224","volume":"100","author":"GAJ Riegger","year":"1999","unstructured":"Riegger GAJ, Bouzo H, Petr P, M\u00fcnz J, Spacek R, Pethig H, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation. 1999;100(22):2224\u201330.","journal-title":"Circulation"},{"issue":"23","key":"686_CR46","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667\u201375.","journal-title":"N Engl J Med"},{"issue":"5","key":"686_CR47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1388-9842(03)00162-4","volume":"5","author":"A Matsumori","year":"2003","unstructured":"Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003;5(5):669\u201377.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"686_CR48","first-page":"H626","volume":"275","author":"A Goussev","year":"1998","unstructured":"Goussev A, Sharov VG, Shimoyama H, Tanimura M, Lesch M, Goldstein S, et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol. 1998;275(2):H626\u201331.","journal-title":"Am J Physiol"},{"issue":"2","key":"686_CR49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/01.HYP.18.2.148","volume":"18","author":"M Pahor","year":"1991","unstructured":"Pahor M, Bernabei R, Sgadari A, Gambassi G Jr, Lo Giudice P, Pacifici L, et al. Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension. 1991;18(2):148\u201357.","journal-title":"Hypertension"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-017-0686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T07:26:14Z","timestamp":1507188374000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-017-0686-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1186\/s12872-017-0686-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]},"article-number":"257"}}